STERIS plc (Ireland)NYSE: STE
Health Care · Health Care Equipment
$207.80
-5.40%
Vol: 35K
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21STERIS posts record FY26 results with 9% revenue growth and authorizes new $1B share buybackMixed▶
STERIS reported Q4 FY26 EPS of $2.83 (missing $2.88 estimate) with revenue of $1.59B, while full-year revenue rose 9% to $5.9B and adjusted EPS climbed to $10.17. The Board authorized a fresh $1B share repurchase program replacing the prior authorization, alongside a $0.63 quarterly dividend. Management guided FY27 reported revenue growth of 7-8% and adjusted EPS of $11.10-$11.30. This signals durable procedure-volume tailwinds and continued capital returns. KeyBanc lowered its price target to $269 from $291 on May 13, indicating some analyst caution despite the buyback authorization.
May 20STERIS posts record FY26 results with $1B buyback authorization but KeyBanc cuts price target to $269Mixed▶
STERIS announced fiscal 2026 full-year revenue up 9% to $5.9B and adjusted EPS of $10.17, though Q4 EPS of $2.83 missed estimates of $2.88 and revenue of $1.588B missed $1.611B consensus. The Board authorized a new $1B share buyback program replacing prior authorization, and the company is investing in a new sterility assurance manufacturing plant in Mentor, Ohio, expected operational by late 2027. FY27 guidance calls for 7-8% reported revenue growth and adjusted EPS of $11.10-$11.30 (9-11% growth). The company declared a $0.63 quarterly dividend payable June 26. KeyBanc lowered its price target to $269 from $291 on May 13. Pierre Boulud was appointed to the board. Stock trades near $212.88.
May 19No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 18STERIS reported FY26 revenue up 9% to $5.9B with adjusted EPS of $10.17 and authorized a new $1 billion share buyback program on May 11.Positive▶
On May 11, 2026, STERIS reported fiscal 2026 Q4 and full-year results with revenue up 9% to $5.9B and adjusted EPS of $10.17, though Q4 EPS of $2.83 missed the $2.88 estimate. Q4 Healthcare revenue rose 7% to $1.14B, AST grew 6% to $289.2M, and Life Sciences grew 9% to $162.9M. The Board authorized a new $1 billion share buyback program, replacing the prior authorization. STERIS announced a strategic investment to build a new sterility assurance manufacturing plant in Mentor, Ohio, operational by late 2027. Fiscal 2027 guidance projects 7-8% revenue growth with adjusted EPS of $11.10-$11.30 (9-11% growth). STE was up 4.04% post-earnings. On May 7, Pierre Boulud was appointed to the Board; a $0.63 quarterly dividend was declared May 5.
May 15STERIS reported FY26 results with revenue up 9% to $5.9B and authorized a new $1B buyback, though Q4 EPS of $2.83 missed by $0.02 and KeyBanc cut its price target to $269 from $291.Mixed▶
On May 11, 2026, STERIS plc reported fiscal 2026 fourth-quarter and full-year results. FY26 revenue grew 9% to $5.9B and Q4 revenue rose 7% to $1.6B, but Q4 adjusted EPS of $2.83 missed by $0.02 triggering a ~2% premarket decline. The board authorized a new $1B share buyback replacing the prior plan and approved a $0.63 quarterly dividend. Pierre Boulud was appointed to the board effective May 5. FY27 guidance calls for adjusted EPS of $11.10-$11.30 (+9-11% vs $10.17) with ~$375M capex including a new sterility-assurance plant in Mentor, Ohio, targeted operational by late 2027. KeyBanc cut PT to $269 from $291 while keeping Buy. Shares traded near $214.70 on May 14. Risk: ongoing margin and capex absorption during plant build-out.
May 14STERIS posted 9% FY26 revenue growth to $5.9B on May 11, authorized $1B buyback and added bioMerieux CEO to boardPositive▶
On May 11, 2026, STERIS reported fiscal Q4 revenue of $1.59B (+7%) and full-year revenue of $5.9B (+9%) with adjusted EPS rising to $10.17. The Board authorized a new $1B share repurchase program and the company is investing $60M in a new sterility assurance plant in Mentor, Ohio (operational late 2027). FY27 guidance: revenue growth 7-8%, adjusted EPS $11.10-$11.30 (+9-11%). On May 7, STERIS appointed bioMerieux CEO Pierre Boulud to the Board. Quarterly dividend of $0.63 declared May 5. Stock rose 4.46% post-earnings on the strong outlook. Risk: Q4 revenue slightly below $1.61B consensus; healthcare capex sensitivity.
May 13STERIS reported FY2026 revenue up 9% to $5.9B, authorized a new $1B share buyback, and guided FY2027 adjusted EPS to $11.10-$11.30 (9-11% growth).Positive▶
STERIS announced FY2026 Q4 and full-year results on May 11, with Q4 revenue up 7% to $1.6B and full-year revenue up 9% to $5.9B (organic growth 7%). Diluted EPS from continuing operations rose to $7.93 and adjusted EPS to $10.17. The board authorized a new $1B buyback and plans a $60M sterility assurance plant in Mentor, Ohio. FY2027 guidance calls for 6-7% organic growth and adjusted EPS of $11.10-$11.30. The board appointed bioMérieux CEO Pierre Boulud as a director and declared a $0.63 quarterly dividend payable June 26.
May 12STERIS reported FY26 revenue +9% to $5.9B, authorized a new $1B buyback, and guided FY27 adjusted EPS to $11.10-$11.30 (+9-11%).Positive▶
STERIS plc on May 11, 2026 reported fiscal 2026 full-year revenue from continuing operations up 9% to $5.9B (7% constant-currency organic) and Q4 revenue +7% to $1.6B. Adjusted diluted EPS for FY26 was $10.17. FY27 guidance: revenue +7-8% (organic 6-7%) and adjusted EPS $11.10-$11.30, implying 9-11% growth. The board authorized a new $1B share buyback program and declared a $0.63 quarterly dividend on May 5. STERIS plans to invest ~$60M over two years to build a new sterility-assurance manufacturing plant in Mentor, Ohio. bioMérieux CEO Pierre Boulud was appointed to the Board. Tariff headwinds remain a flagged risk for margins.
May 11STERIS declares $0.63 dividend and appoints Pierre Boulud to board ahead of Q4/FY26 earnings May 11-12Neutral▶
STERIS announced a $0.63 quarterly dividend on May 5 payable June 26 to record date June 8, and appointed Pierre Boulud to its board effective May 5. Q4 FY26 results are due Monday May 11 after the close with a conference call May 12 at 9:00 a.m. ET. Consensus expects $2.86 EPS and $1.5946B revenue (~5.5% YoY diluted EPS growth). Wall Street Zen cut STE from Strong Buy to Buy on April 26, and Weiss Ratings cut to Hold from Buy on April 16. The stock has an average Moderate Buy rating with $275.20 average PT.
May 8STERIS announced quarterly dividend of $0.63/share and appointed Pierre Boulud (bioMerieux CEO) to board; fiscal Q4 results scheduled for May 12.Neutral▶
STERIS announced $0.63 quarterly dividend per share and appointed Pierre Boulud, CEO of bioMerieux (in vitro diagnostics leader since 2023), to Board of Directors effective May 5, 2026. Company hosts fiscal Q4 and full-year results conference call May 12, 2026, with expectations for $1.60B revenue and $2.89 EPS. Medical equipment provider reported Q2 FY2026 EPS of $2.53 (hit consensus) with 9.2% quarterly revenue growth YoY. 5 analysts rate as Buy with average 12-month PT of $275.2 (implying 29.22% upside). Stock at $214.46 with 0.9% weekly gain but 2.5% 30-day decline and 14.2% YTD decline.
May 7STERIS plc announced a $0.63 per share quarterly dividend and scheduled Q4 2026 earnings release for May 12.Neutral▶
STERIS plc announced a $0.63 per share quarterly dividend (unchanged from prior quarter) on May 5, 2026, with record date June 8 and payment date June 26. The company is preparing for Q4 fiscal 2026 earnings release scheduled for May 12, 2026, with analysts expecting $2.89 adjusted EPS. Q3 fiscal 2026 showed 9% revenue growth and 9% EPS growth with strong segment performance and robust free cash flow, despite tariff headwinds. The company maintained fiscal 2026 guidance.
May 6STERIS declares $0.63 quarterly dividend; Q4 earnings call scheduled for May 12Neutral▶
STERIS plc announced quarterly dividend of $0.63 per share payable June 26, 2026. Q3 earnings of $2.53 EPS matched consensus. Revenue up 9.2% year-over-year with 9% EPS growth. Fiscal 2026 fourth quarter and full year results conference call scheduled for May 12, 2026. Average analyst rating is Buy with 12-month price target of $275.2, representing 29.22% upside.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| STESTERIS | $207.80 | -5.40% | +3.2% | 18.1x | 0.95 | $21.6B |
| ISRGINTUITIVE | $416.51 | -5.30% | -0.0% | 37.3x | 1.51 | $155.8B |
| ABTABBOTT | $88.21 | +0.50% | -0.2% | 14.5x | 0.65 | $152.9B |
| SYKSTRYKER | $310.30 | -1.02% | +0.1% | 18.8x | 0.81 | $120.2B |
| MDTMEDTRONIC | $80.25 | +2.69% | +1.1% | 12.9x | 0.63 | $100.3B |
| BSXBOSTON | $47.37 | -17.11% | +2.2% | 15.2x | 0.62 | $84.9B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.